• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Egfr and eml4-alk updated therapies in non-small cell lung cancer

Thumbnail
Date
2016
Author
de Mello, Ramon Andrade
Liu, Davi J. J. [UNIFESP]
Aguiar, Pedro N., Jr. [UNIFESP]
Tadokoro, Hakaru [UNIFESP]
Type
Revisão
ISSN
1574-8928
Is part of
Recent Patents On Anti-Cancer Drug Discovery
DOI
10.2174/1574892811666160803090944
Metadata
Show full item record
Abstract
Background: Non-small cell lung cancer is the leading cancer-related cause of death. Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents. Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant. Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies. Conclusions: Currently, EGFR TKIs (e. g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Citation
Recent Patents On Anti-Cancer Drug Discovery. Sharjah, v. 11, n. 4, p. 393-400, 2016.
Keywords
Afatinib
Egfr
Elm4-Alk
Erlotinib
Geftinib
Non-Small Cell Lung Cancer
Osimertinib
PatentTyrosine Kinase Inhibitors
T790m Mutation
1st-Line Treatment
Open-Label
Phase-Iii
Chemotherapy
Gefitinib
Erlotinib
Trial
Crizotinib
URI
http://repositorio.unifesp.br/handle/11600/49265
Collections
  • EPM - Artigos [17701]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV